Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

about

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.

P2860

Q47124210-C167976B-2C66-4CE3-AD97-82B34363BBE1

P2860

Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

Item

http://www.wikidata.org/entity/Q38707832

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Adjuvant chemotherapy for colo ...... panese and western strategies.

@en

type

Item

label

Adjuvant chemotherapy for colo ...... panese and western strategies.

@en

prefLabel

Adjuvant chemotherapy for colo ...... panese and western strategies.

@en

P1476

Adjuvant chemotherapy for colo ...... panese and western strategies.

@en

P2093

Kenichi Sugihara

http://www.w3.org/2001/XMLSchema#string

Yasushi Tsuji

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).

Capecitabine as adjuvant treatment for stage III colon cancer.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

P304

783-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2016.1145665

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26799310

http://www.w3.org/2001/XMLSchema#string

Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

about

P2860

P2860

Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698